Biotronik has announced a strategic distribution agreement with CardioFocus to advance ablation treatment for cardiac arrhythmias, with Biotronik serving as the exclusive distributor of the Centauri pulsed field ablation (PFA) system in selected European countries.
A Biotronik press release states that this collaboration represents a significant milestone in the commercial expansion of Centauri—a next-generation focal PFA system that provides physicians with a highly controllable and versatile solution for cardiac ablation in the treatment of paroxysmal atrial fibrillation (AF). The release adds that Centauri stands out for its compatibility with widely used mapping systems, flexible workflow integration, and an “unmatched” body of real-world evidence, positioning the device as a “frontrunner” in the field of focal PFA.
“We are proud to collaborate with CardioFocus to expand the reach of the Centauri system in key European markets,” said Andreas Hecker, president of cardiac rhythm management (CRM) and electrophysiology (EP) at Biotronik. “As PFA evolves, hospitals increasingly need solutions that combine strong clinical performance with flexibility. This collaboration reflects our ongoing commitment to advancing innovation in EP and supporting physicians in improving patient outcomes.”
The Centauri system is CE-marked and has been used to treat over 8,000 patients across Europe. Clinical experience reported in more than 40 publications has demonstrated a high level of procedural efficiency, durable cardiac lesions, and a low rate of complications, Biotronik’s release further claims.
The recently announced partnership is intended to enhance AF treatment options via the Centauri system across a total of 17 European markets.
“We are thrilled to partner with a company as well-established and clinically trusted as Biotronik to bring our technology to more physicians and patients across Europe,” commented Steve Ogilvie, chief executive officer (CEO) of CardioFocus. “Biotronik’s deep EP expertise, expansive global presence and commitment to physician training make [it] the ideal partner to support the next phase of Centauri’s growth.”
